| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Departments of Neurology (M.M., V.A.L., A.J., S.J.P., C.F.L., B.G.W.), and Laboratory Medicine and Pathology (V.A.L., S.J.P.), Mayo Clinic College of Medicine, Rochester, MN; and Department of Neurology (D.M.W.), Mayo Clinic College of Medicine, Scottsdale, AZ.
* To whom correspondence should be addressed. E-mail: weinb{at}mayo.edu.
Objective: To determine the prognostic value of neuromyelitis optica (NMO)–immunoglobulin G (IgG) in patients with recurrent optic neuritis (ON). The aquaporin-4-specific serum autoantibody, NMO-IgG, is a biomarker for NMO and relapsing transverse myelitis. Recurrent ON may herald multiple sclerosis (MS) or NMO, or it may occur as an isolated syndrome. The prognosis and response to therapy differs in each of these contexts.
Methods: We evaluated 34 patients who were tested for NMO-IgG between 2000 and 2007 and who had two or more episodes of ON without satisfying a diagnosis of MS or NMO prior to serologic testing. Clinical data were available for 25 Mayo Clinic patients (5 NMO-IgG positive and 20 NMO-IgG negative) and for an additional 9 seropositive patients whose serum was referred to the Mayo Clinic Neuroimmunology laboratory for testing.
Results: Twenty percent of the patients with recurrent ON seen at Mayo Clinic were seropositive. All NMO-IgG-positive patients (vs 65% NMO-IgG-negative patients) had at least one attack with visual acuity in the affected eye worse than 20/200 (p = 0.05). In seropositive patients for whom long-term follow-up was possible (median 8.9 years after the initial ON), 6 of 12 (50%) experienced an episode of myelitis and fulfilled criteria for NMO. In contrast, 1 of 15 seronegative patients (6.7%) fulfilled McDonald criteria for MS (p = 0.03). Seropositive patients had a final visual score which was worse than that of seronegative patients (p = 0.02).
Conclusions: Neuromyelitis optica (NMO)–immunoglobulin G seropositivity predicts poor visual outcome and development of NMO. Seropositive recurrent optic neuritis is a limited form of NMO.
This article has been cited by other articles:
|
|
 |
|
  L. A E Matthews, F. Baig, J. Palace, and M. R Turner The borderland of neuromyelitis optica Practical Neurology, December 1, 2009; 9(6): 335 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. De Jager Review: Identifying patient subtypes in multiple sclerosis and tailoring immunotherapy: challenges for the future Therapeutic Advances in Neurological Disorders, November 1, 2009; 2(6): 369 - 377. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Jacob, M. Matiello, B. G. Weinshenker, D. M. Wingerchuk, C. Lucchinetti, E. Shuster, J. Carter, B. M. Keegan, O. H. Kantarci, and S. J. Pittock Treatment of Neuromyelitis Optica With Mycophenolate Mofetil: Retrospective Analysis of 24 Patients Arch Neurol, September 1, 2009; 66(9): 1128 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. McKeon, J. P. Fryer, M. Apiwattanakul, V. A. Lennon, S. R. Hinson, T. J. Kryzer, C. F. Lucchinetti, B. G. Weinshenker, D. M. Wingerchuk, E. A. Shuster, et al. Diagnosis of Neuromyelitis Spectrum Disorders: Comparative Sensitivities and Specificities of Immunohistochemical and Immunoprecipitation Assays Arch Neurol, September 1, 2009; 66(9): 1134 - 1138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Cabrera-Gomez, M Bonnan, A Gonzalez-Quevedo, A Saiz-Hinarejos, R Marignier, S Olindo, F Graus, D Smadja, H Merle, L Thomas, et al. Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies Multiple Sclerosis, July 1, 2009; 15(7): 828 - 833. [Abstract] [PDF]
|
|
|
|
|
|
H Zephir, I Fajardy, O Outteryck, F Blanc, N Roger, M Fleury, G Rudolf, R Marignier, S Vukusic, C Confavreux, et al. Is neuromyelitis optica associated with human leukocyte antigen? Multiple Sclerosis, May 1, 2009; 15(5): 571 - 579. [Abstract] [PDF]
|
|
|
|
 |
|
 E. C. Klawiter, E. Alvarez III, J. Xu, A. R. Paciorkowski, L. Zhu, B. J. Parks, A. H. Cross, and R. T. Naismith NMO-IgG DETECTED IN CSF IN SERONEGATIVE NEUROMYELITIS OPTICA Neurology, March 24, 2009; 72(12): 1101 - 1103. [Full Text] [PDF]
|
|
|
|
|
|
S. M. Magana, M. Matiello, S. J. Pittock, A. McKeon, V. A. Lennon, A. A. Rabinstein, E. Shuster, O. H. Kantarci, C. F. Lucchinetti, and B. G. Weinshenker Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders Neurology, February 24, 2009; 72(8): 712 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Miller, B. Weinshenker, M Filippi, B. Banwell, J. Cohen, M. Freedman, S. Galetta, M Hutchinson, R. Johnson, L Kappos, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach Multiple Sclerosis, November 1, 2008; 14(9): 1157 - 1174. [Abstract] [PDF]
|
|
|
|
|
|
C. H. Smith Neuromyelitis Optica and the Optic Neuritis Treatment Trial--Reply Arch Neurol, November 1, 2008; 65(11): 1546 - 1546. [Full Text] [PDF]
|
|
|
|
 |
|
 NMO-IgG Predicts Outcome of Recurrent Optic Neuritis Journal Watch Neurology, September 9, 2008; 2008(909): 6 - 6. [Full Text]
|
|
|
|
|
|
G. Giovannoni To test or not to test: NMO-IgG and optic neuritis Neurology, June 3, 2008; 70(23): 2192 - 2193. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
